Hypophyllanthin
(Synonyms: (7S,8S,9R)-9-(3,4-二甲氧基苯基)-6,7,8,9-四氢-4-甲氧基-7,8-双(甲氧基甲基)萘并[1,2-D]-1,3-二恶茂,NSC 619044) 目录号 : GC10391A P-glycoprotein inhibitor
Cas No.:33676-00-5
Sample solution is provided at 25 µL, 10mM.
Hypophyllanthin is a P-glycoprotein (P-gp) inhibitor.
P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2), two major drug efflux pumps, play a key role in the translocation of certain drugs and xenobiotics via restrictive barriers. The presence of P-gp and other efflux transporters on the apical membrane of enterocytes can limit absorption and therefore oral bioavailability. Inhibition of the activity of these transporters can increase plasma levels of various drugs that are their substrates, resulting in changes in drug efficacy and adverse reactions.
In vitro: Previous study found that hypophyllanthin could inhibit P-gp function with comparable potencies, but could not affect MRP2 activity. When hypophyllanthin was washed out before addition of substrate, the inhibitory action against P-gp function was lost. These results indicated the reversibility of the inhibition. Moreover, prolonged exposure of the Caco-2 cells to hypophyllanthin up to 7 days had no effect on P-gp function [1].
In vivo: A previous study was conducted to evaluate the effect of carbofuran on estrous cycle and follicular growth in virgin Wister rats as well as recovering from the damaged estrous cycle with treatment of hypophyllanthin. Hypophyllanthin is non-steroidal plant molecule with estrogen-like activities, but with an estrogen-type activity. Hypophyllanthin was capable of interacting with estrogen receptors, showing both agonist and antagonist methods of action. Therefore, hypophyllanthin was found to be systemically transformed into enterolignan, which is known to be responsible for augmenting estrus cycle in rats [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] N. Sukhaphirom, N. Vardhanabhuti, H. Chirdchupunseree, et al. Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. Journal of Pharmacy and Pharmacology 65, 292-299 (2012).
[2] Aminul Islam et al. Estrogenic Properties of Phyllanthin and Hypophyllanthin from Phyllanthus amarus against Carbofuran Induced Toxicity in Female Rats. Pharmacologyonline 3: 1006-1016 (2008).
Cas No. | 33676-00-5 | SDF | |
别名 | (7S,8S,9R)-9-(3,4-二甲氧基苯基)-6,7,8,9-四氢-4-甲氧基-7,8-双(甲氧基甲基)萘并[1,2-D]-1,3-二恶茂,NSC 619044 | ||
化学名 | (7S,8S,9R)-9-(3,4-dimethoxyphenyl)-6,7,8,9-tetrahydro-4-methoxy-7,8-bis(methoxymethyl)-naphtho[1,2-d]-1,3-dioxole | ||
Canonical SMILES | COC[C@@H]1[C@@H](COC)CC(C=C(OC)C2=C3OCO2)=C3[C@H]1C4=CC(OC)=C(OC)C=C4 | ||
分子式 | C24H30O7 | 分子量 | 430.5 |
溶解度 | ≤0.2mg/ml in ethanol;10mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3229 mL | 11.6144 mL | 23.2288 mL |
5 mM | 0.4646 mL | 2.3229 mL | 4.6458 mL |
10 mM | 0.2323 mL | 1.1614 mL | 2.3229 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet